eyeforpharma Barcelona 2016 conference

eyeforpharma 15 - 17 March 2016, Barcelona, Spain.
eyeforpharma Barcelona will set the vision for your 2020 plans. With 120% attendee growth you can join 1000+ industry leaders in commercial excellence, patient engagement and innovation at the unmissable pharma-stakeholder summit. As your customer takes charge this meeting will enable you take the steps you need to become their partner of choice.

The conference will bring together all key stakeholders, so you can collaborate and identify solutions in order to:

  • Gain Real Customer Insight. Reinvent your understanding of customer experience with a holistic multichannel solution
  • Deliver Outcomes. Enhance patient experience by partnering with external stakeholders and facilitating internal cross functionality
  • Sell Value. Engage the busier, more informed customer with impactful face-to-face, remote and digital communication
  • Develop a New Corporate Culture. Pioneer a progressive internal mind-set promoting collaboration, communication and trust

Why Attend?
90+ industry leading speakers including C-Suite, VP and Director level experts to share their experiences so you can make healthier corporate decisions. 2016 speakers include:


  • David Epstein, Novartis, Division Head and CEO Pharmaceuticals
  • Dominique Limet, ViiV, Healthcare
  • Jane Griffiths, Janssen, Company Group Chairman, Europe, Middle East & Africa
  • Gitte Aabo, LEO Pharma, CEO
  • Eduardo Javier Sanchiz Yrazu, Almirall, CEO
  • Murray Stewart, GSK, Chief Medical Officer
  • Tim Kneen, Merck, Executive President, Europe & Canada
  • David Loew, Sanofi Pasteur, COO
  • Andrew Hotchkiss, Eli Lilly and Company, President Europe and Canada
  • Jason DeGoes, Teva, SVP Patient Solutions

Patient Experience

  • Kasper Jerlang, LEO Pharma, Head - Global Patient Communications
  • Sanja Njegic, Novartis, Director Patient Relations, Europe
  • Henrik Finnern, Boehringer Ingelheim, Chief Patient Office
  • Anne Beal, Sanofi, Chief Patient Officer
  • Paul Robinson, MSD, Executive Director Scientific Medical and Patient Perspective

Commercial Excellence

  • Andreas Wandelt, Pfizer, Vice President, Global Sales and Marketing Services
  • Heléna Bargiel, LEO Pharma, Head of Global Field Force Excellence
  • Etienne Tichit, Novo Nordisk, Vice President, Commercial Excellence
  • Bharat Tewarie, UCB, EVP & Chief Marketing Officer
  • Chris-Carol Bremer, Grunenthal, SVP & Head of Marketing

See the complete speaker line-up here.

Don't miss Barcelona 2016, Europe’s premier pharmaceutical summit in commercial excellence, patient engagement and innovation!

Save €100 using World Pharma News unique code wpn100

For further information, please visit:

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]